Diadia
Our TechnologyResearchResourcesAboutLoginBook a call

© 2026 Diadia. All rights reserved.

About UsOur TechnologyResearchResourcesResearch
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions
About UsOur TechnologyResearchResourcesResearch
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions

© 2026 Diadia. All rights reserved.

←Transparency Reports

cardiovascular · Mechanism Report

Can inherited LPA variation cause a persistent atherogenic burden?

Inherited LPA variation is the main determinant of markedly elevated lipoprotein(a), which can create a persistent atherogenic particle burden.

PlausibleNovember 21, 20269 Sources

Reasoning Paths

Each route from condition to outcome carries a support score — the product of its edge weights. Select one to isolate it on the figure.

This is what AI claimed

Inherited variation in LPA is the principal determinant of markedly elevated lipoprotein(a) and can cause a persistent atherogenic lipoprotein burden.

laying out figure…
1 of 3 paths supported
UnsupportedPlausibleSupported

How to read the figure

Evidence state

  • ●EstablishedStrong, replicated evidence.
  • ◐ModerateEvidence-informed; limited or moderate.
  • ◇PlausibleMechanistically coherent, not established.
  • ✕UnsupportedTested and not supported — link breaks.
  • ?MissingNo evidence either way — untested.

Node shapes

  • BiomarkerA measurable state — a lab value, hormone, or genetic factor.
  • ProcessA biological process, pathway, or mechanism step.
  • ConditionA condition, exposure, intervention, or symptom.
  • OutcomeThe endpoint the claim leads to.

Executive summary

LPA variants, particularly those affecting apo(a) size, strongly influence lipoprotein(a) concentrations. Each lipoprotein(a) particle contains apoB, contributing to a persistent particle burden and increased atherosclerotic cardiovascular risk.

Verified conclusion

Markedly elevated lipoprotein(a) [Lp(a)] is best understood as a predominantly inherited, durable source of atherogenic apoB-containing particles and cardiovascular risk.

Genetic and clinical evidence

  • Inherited variation at LPA is the principal determinant of high Lp(a). Kringle IV type 2 (KIV-2) copy-number variation is especially important: fewer repeats produce smaller apo(a) isoforms and generally higher Lp(a) concentrations. Apo(a) isoform size explains roughly 30–70% of concentration variance, and estimated Lp(a) heritability is commonly 70–90%.
  • Genetic effects are polyvariant and ancestry-dependent. KIV2 copy number explained 18% of Lp(a) variation in European and 26% in African American participants; adding other independent LPA variants increased explained variation to 45–49%. In European-ancestry populations, rs10455872 and rs3798220 together explained 36% of variation.
  • High Lp(a) is causally and dose-dependently associated with atherosclerotic cardiovascular disease (ASCVD), supported by epidemiologic and Mendelian-randomization evidence.

Atherogenic burden and persistence

  • Each Lp(a) particle carries one apoB-100 molecule, so it directly contributes to total apoB particle number. In a cohort of 158,260 people, Lp(a) represented about 3% of apoB particles overall but ~15% in the highest Lp(a) decile.
  • This burden is persistent: over a median 4.4 years, Lp(a) showed very high repeat agreement (ICC 0.974), exceeding that of LDL-C, apoB, and triglycerides.
  • ApoB is the most complete routine marker of this particle burden because it includes Lp(a), LDL, and other apoB-containing particles. LDL particle number alone may not capture the Lp(a) contribution.

Bottom line

  • The claim is supported: inherited LPA variation is the dominant cause of markedly elevated Lp(a), which can create a sustained, clinically meaningful atherogenic apoB burden. This does not require elevated non-Lp(a) LDL particles; interpretation should integrate apoB and overall ASCVD risk.

References

  1. Deep coverage whole genome sequences and plasma lipoprotein(a) in individuals of European and African ancestries - Nature Communications — link.springer.com ↗
  2. Genetic Variants Associated with Lp(a) Lipoprotein Level and ... — nejm.org ↗
  3. Lipoprotein(a) beyond the kringle IV repeat polymorphism - PMC — pmc.ncbi.nlm.nih.gov ↗
  4. Non-genetic influences on lipoprotein(a) concentrations - PMC — pmc.ncbi.nlm.nih.gov ↗
  5. Quantifying the contribution of lipoprotein(a) to all apoB containing ... — pubmed.ncbi.nlm.nih.gov ↗
  6. Within-person stability of lipoprotein (a) concentration — academic.oup.com ↗
  7. Longitudinal changes and borderline reclassification of Lipoprotein(a) compared with conventional lipids in over 230,000 adults - PubMed — pubmed.ncbi.nlm.nih.gov ↗
  8. Lipoprotein(a) as a Causal Risk Factor for Cardiovascular Disease - Current Cardiovascular Risk Reports — link.springer.com ↗
  9. Lipoprotein(a) as a Causal Risk Factor for Cardiovascular Disease — ncbi.nlm.nih.gov ↗

See a full patient report verified like this

Book a walkthrough

Related Claims

Plausible6 sourcesCan correcting an omega-3 imbalance reduce ApoB-containing lipoproteins?→Plausible7 sourcesCan saturated fat raise LDL cholesterol and ApoB?→